145 related articles for article (PubMed ID: 7907237)
21. Comparative cytotoxicities of a series of ellipticine and olivacine derivatives on multidrug resistant cells of human and murine origins.
Chevallier-Multon MC; Jacquemin-Sablon A; Besselièvre R; Husson HP; Le Pecq JB
Anticancer Drug Des; 1990 Nov; 5(4):319-35. PubMed ID: 1981310
[TBL] [Abstract][Full Text] [Related]
22. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
[TBL] [Abstract][Full Text] [Related]
23. Identification of a P-glycoprotein-related protein (mini-P-glycoprotein) which is overexpressed in multidrug resistant cells.
Kawai K; Kusano I; Ido M; Sakurai M; Shiraishi T; Yatani R
Biochem Biophys Res Commun; 1994 Jan; 198(2):804-10. PubMed ID: 7905266
[TBL] [Abstract][Full Text] [Related]
24. Anthracyclines.
Sinha BK; Politi PM
Cancer Chemother Biol Response Modif; 1990; 11():45-57. PubMed ID: 2223402
[TBL] [Abstract][Full Text] [Related]
25. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
Lothstein L; Savranskaya L; Sweatman TW
Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856
[TBL] [Abstract][Full Text] [Related]
26. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I
J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746
[TBL] [Abstract][Full Text] [Related]
27. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.
Abbaszadegan MR; Cress AE; Futscher BW; Bellamy WT; Dalton WS
Cancer Res; 1996 Dec; 56(23):5435-42. PubMed ID: 8968098
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells.
Molnár J; Hevér A; Fakla I; Fischer J; Ocsovski I; Aszalós A
Anticancer Res; 1997; 17(1A):481-6. PubMed ID: 9066699
[TBL] [Abstract][Full Text] [Related]
29. Flavonoid-related modulators of multidrug resistance: synthesis, pharmacological activity, and structure-activity relationships.
Ferté J; Kühnel JM; Chapuis G; Rolland Y; Lewin G; Schwaller MA
J Med Chem; 1999 Feb; 42(3):478-89. PubMed ID: 9986718
[TBL] [Abstract][Full Text] [Related]
30. Reversal of P-glycoprotein associated multidrug resistance by new isoprenoid derivatives.
Hayashi M; Koike K; Rho MC; Kuwano M; Kishiye T; Komiyama K
Anticancer Drug Des; 2001; 16(4-5):255-60. PubMed ID: 12049484
[TBL] [Abstract][Full Text] [Related]
31. Preparation and utility of a radioiodinated analogue of daunomycin in the study of multidrug resistance.
Busche R; Tümmler B; Riordan JR; Cano-Gauci DF
Mol Pharmacol; 1989 Apr; 35(4):414-21. PubMed ID: 2565017
[TBL] [Abstract][Full Text] [Related]
32. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein.
Krishnamachary N; Center MS
Cancer Res; 1993 Aug; 53(16):3658-61. PubMed ID: 8101765
[TBL] [Abstract][Full Text] [Related]
33. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells.
Slapak CA; Fracasso PM; Martell RL; Toppmeyer DL; Lecerf JM; Levy SB
Cancer Res; 1994 Nov; 54(21):5607-13. PubMed ID: 7923205
[TBL] [Abstract][Full Text] [Related]
35. Resistance and cross-resistance of cultured leukemia P388 cells to vincristine, adriamycin, adriamycin analogs, and actinomycin D.
Wilkoff LJ; Dulmadge EA
J Natl Cancer Inst; 1978 Dec; 61(6):1521-4. PubMed ID: 281559
[TBL] [Abstract][Full Text] [Related]
36. Structurally modified anthracyclines retain activity in a cell line with simultaneous typical and atypical multidrug resistance.
Bielack SS; Kallenbach K; Looft G; Erttmann R; Winkler K
Anticancer Res; 1995; 15(4):1279-84. PubMed ID: 7654009
[TBL] [Abstract][Full Text] [Related]
37. P-glycoprotein overexpression in mouse cells does not correlate with resistance to N-benzyladriamycin-14-valerate (AD 198).
Lothstein L; Koseki Y; Sweatman TW
Anticancer Drugs; 1994 Dec; 5(6):623-33. PubMed ID: 7888699
[TBL] [Abstract][Full Text] [Related]
38. Pharmacology of N,N-di(n-butyl)adriamycin-14-valerate in the rat.
Han G; Israel M; Seshadri R; Dalton JT; Sweatman TW
Cancer Chemother Pharmacol; 1996; 37(5):472-8. PubMed ID: 8599871
[TBL] [Abstract][Full Text] [Related]
39. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Rouse W; Riegler F
Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
[TBL] [Abstract][Full Text] [Related]
40. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
Friche E; Demant EJ; Sehested M; Nissen NI
Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
